Gilead buys what it tried with Tubulis
A $3.15bn deal follows a December 2024 option agreement.
ESMO 2025 preview – Merck hopes for Daiichi redemption
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
Gilead and GSK nab early ADCs
Gilead links up with Tubulis, while GSK taps BioNTech’s partner DualityBio.
No SOS for Bayer's SOS1
The group goes after a KRAS-related target on which Boehringer recently gave up.
Boundless and others head for phase 1
First-in-human study initiations include Boundless Bio’s second asset, and an ADC from Tubulis.
